Aimfinity Investment Corp. I
AIMAW
NASDAQ Global Market0.05
USD
+0.05
- -
CIK
0001903464
ISIN
KYG0135E1263
CUSIP
G0135E126
Return %
Stock
S&P500
1Y
-35.62
18.21
3Y
-12.62
64.38
5Y
-10.00
72.43
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- I-Fa Chang
- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- 1 Rockefeller Plaza New York City NY United States of America 10020
- IPO Date
- Jun 16, 2022
- CIK
- 0001903464
- Similar Companies
- Business
- Aimfinity Investment Corp. I (AIMAW) operates as a blank check company, or special purpose acquisition company (SPAC), whose principal business activity focuses on effecting mergers, share exchanges, asset acquisitions, share purchases, reorganizations, or similar business combinations with one or more businesses; it targets opportunities primarily in the technology, hospitality, and consumer services sectors. The company offers no operational products or services of its own but facilitates public market access for private targets through its SPAC structure, holding raised capital in trust for deployment in such combinations; key elements include structured merger processes, transparent governance via shareholder meetings and regulatory filings, and capital protection mechanisms until a deal closes. Incorporated in 2021 and headquartered in Wilmington, Delaware, Aimfinity Investment Corp. I functions as a subsidiary of Aimfinity Investment LLC and conducts global operations excluding China, Hong Kong, and Macau. Recent developments include multiple extensions of its initial business combination deadline, with shareholders approving amendments in November 2025 to extend up to nine one-month periods through July 2026; ongoing pursuit of a merger with Docter Inc., a Taiwanese developer of non-invasive blood glucose monitoring watches and health tracking cloud platforms, originally announced in October 2023 with $60M consideration and earnouts tied to 2024-2025 sales targets, featuring reincorporation into a new PubCo entity; a new securities purchase agreement in October 2025 with Inkrock Holding Limited and CEO I-Fa Chang for acquisition via 687,054 ordinary shares concurrent with the Docter closing, following termination of a prior May 2025 deal; agreements in June 2025 for satisfaction of indebtedness with IPO underwriters D. Boral Capital and US Tiger Securities contingent on the business combination; and a transition from Nasdaq to OTC Markets trading in 2025 amid extension efforts.